182 related articles for article (PubMed ID: 31102498)
21. Efficacy and safety of off-label use of rituximab in refractory lupus: data from the Italian Multicentre Registry.
Iaccarino L; Bartoloni E; Carli L; Ceccarelli F; Conti F; De Vita S; Ferraccioli G; Galeazzi M; Gatto M; Gerli R; Govoni M; Gremese E; Iuliano A; Mansutti E; Moroni G; Mosca M; Nalli C; Naretto C; Padovan M; Palma L; Raffiotta F; Roccatello D; Tincani A; Valesini G; Zen M; Doria A
Clin Exp Rheumatol; 2015; 33(4):449-56. PubMed ID: 26053285
[TBL] [Abstract][Full Text] [Related]
22. Predictive and prognostic factors influencing outcomes of rituximab therapy in systemic lupus erythematosus (SLE): A systematic review.
Pirone C; Mendoza-Pinto C; van der Windt DA; Parker B; O Sullivan M; Bruce IN
Semin Arthritis Rheum; 2017 Dec; 47(3):384-396. PubMed ID: 28602359
[TBL] [Abstract][Full Text] [Related]
23. [Long-term follow-up of patients with refractory systemic lupus erythematosus during rituximab treatment].
Tsanian MÉ; Solov'ev SK; Torgashina AV; Aleksandrova EN; Radenska-Lopovok SG; Nikolaeva EV; Khrennikova IaB; Nasonov EL
Ter Arkh; 2014; 86(5):40-9. PubMed ID: 25026801
[TBL] [Abstract][Full Text] [Related]
24. Safety and efficacy of rituximab in refractory pediatric systemic lupus erythematosus nephritis: a single-center experience of Northern Greece.
Trachana M; Koutsonikoli A; Farmaki E; Printza N; Tzimouli V; Papachristou F
Rheumatol Int; 2013 Mar; 33(3):809-13. PubMed ID: 22101555
[TBL] [Abstract][Full Text] [Related]
25. Rituximab for remission induction in elderly patients with ANCA-associated vasculitis.
Timlin H; Lee SM; Manno RL; Seo P; Geetha D
Semin Arthritis Rheum; 2015 Aug; 45(1):67-9. PubMed ID: 25796088
[TBL] [Abstract][Full Text] [Related]
26. Rituximab in systemic lupus erythematosus: an updated systematic review and meta-analysis.
Duxbury B; Combescure C; Chizzolini C
Lupus; 2013 Dec; 22(14):1489-503. PubMed ID: 24135078
[TBL] [Abstract][Full Text] [Related]
27. Efficacy of repeat-dose rituximab maintenance therapy for minimal change disease in adults.
Taguchi S; Ohtake T; Mochida Y; Ishioka K; Moriya H; Hidaka S; Kobayashi S
Clin Exp Nephrol; 2020 Dec; 24(12):1132-1139. PubMed ID: 32761467
[TBL] [Abstract][Full Text] [Related]
28. Anti CD20 (Rituximab) therapy in refractory pediatric rheumatic diseases.
Reis J; Aguiar F; Brito I
Acta Reumatol Port; 2016; 41(1):45-55. PubMed ID: 27115107
[TBL] [Abstract][Full Text] [Related]
29. Safety and efficacy of rituximab in childhood-onset systemic lupus erythematosus and other rheumatic diseases.
Tambralli A; Beukelman T; Cron RQ; Stoll ML
J Rheumatol; 2015 Mar; 42(3):541-6. PubMed ID: 25593242
[TBL] [Abstract][Full Text] [Related]
30. Successful early rituximab treatment in a case of systemic lupus erythematosus with potentially fatal diffuse alveolar hemorrhage.
Na JO; Chang SH; Seo KH; Choi JS; Lee HS; Lyu JW; Nah SS
Respiration; 2015; 89(1):62-5. PubMed ID: 25531296
[TBL] [Abstract][Full Text] [Related]
31. Predictors of relapse and long-term outcome in children with steroid-dependent nephrotic syndrome after rituximab treatment.
Fujinaga S; Hirano D; Mizutani A; Sakuraya K; Yamada A; Sakurai S; Shimizu T
Clin Exp Nephrol; 2017 Aug; 21(4):671-676. PubMed ID: 27558467
[TBL] [Abstract][Full Text] [Related]
32. Low-dose rituximab therapy in steroid-refractory thrombocytopenia due to systemic lupus erythematosus.
Ilizaliturri-Guerra O; Uriarte-Botello R; Pineda-Sic RÁ; Serna-Peña G; Garza-Elizondo MA; Galarza-Delgado DÁ; Leal-Bramasco AS; Elizondo-Solís CV; Santoyo-Fexas L; Villarreal-Alarcón MÁ
Rheumatol Int; 2020 Oct; 40(10):1717-1724. PubMed ID: 32797277
[TBL] [Abstract][Full Text] [Related]
33. Can we predict if patients with SLE will require more than one cycle of rituximab?
Fernández González R; Abida R; Gisca E; Duarte L; Isenberg DA
Rheumatology (Oxford); 2022 May; 61(5):1892-1899. PubMed ID: 34240116
[TBL] [Abstract][Full Text] [Related]
34. The NET-effect of combining rituximab with belimumab in severe systemic lupus erythematosus.
Kraaij T; Kamerling SWA; de Rooij ENM; van Daele PLA; Bredewold OW; Bakker JA; Bajema IM; Scherer HU; Toes REM; Huizinga TJW; Rabelink TJ; van Kooten C; Teng YKO
J Autoimmun; 2018 Jul; 91():45-54. PubMed ID: 29636274
[TBL] [Abstract][Full Text] [Related]
35. Consolidation Treatment and Long-Term Prognosis of Rituximab in Minimal Change Disease and Focal Segmental Glomerular Sclerosis.
Lin L; Wang W; Wu Y; Xie J; Li X; Pan X; Zhang W; Xu J; Cai Y; Ren H; Chen N
Drug Des Devel Ther; 2021; 15():1945-1953. PubMed ID: 34007154
[TBL] [Abstract][Full Text] [Related]
36. Efficacy of Whole-Blood Exchange Transfusion in Refractory Severe Autoimmune Haemolytic Anaemia Secondary to Systemic Lupus Erythematosus: A Real-World Observational Retrospective Study.
Jiang Y; Zhao HJ; Luo H; Li BJ; Zhang ZM; Zhao LD; Zuo XX
Front Immunol; 2022; 13():861719. PubMed ID: 35757744
[TBL] [Abstract][Full Text] [Related]
37. Hydroxychloroquine and COVID-19: can we learn from the use of rituximab in systemic lupus erythematosus?
Lekpa FK; Ngahane BHM; Njonnou SRS; Fouda H; Halle MP; Njankouo YM; Dzudie A; Choukem SP; Luma HN
Pan Afr Med J; 2021; 38():372. PubMed ID: 34367451
[TBL] [Abstract][Full Text] [Related]
38. Baseline autoantibody profiles predict normalization of complement and anti-dsDNA autoantibody levels following rituximab treatment in systemic lupus erythematosus.
Tew GW; Rabbee N; Wolslegel K; Hsieh HJ; Monroe JG; Behrens TW; Brunetta PG; Keir ME
Lupus; 2010 Feb; 19(2):146-57. PubMed ID: 19946034
[TBL] [Abstract][Full Text] [Related]
39. Study protocol: mycophenolate mofetil as maintenance therapy after rituximab treatment for childhood-onset, complicated, frequently-relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicenter double-blind, randomized, placebo-controlled trial (JSKDC07).
Horinouchi T; Sako M; Nakanishi K; Ishikura K; Ito S; Nakamura H; Oba MS; Nozu K; Iijima K
BMC Nephrol; 2018 Nov; 19(1):302. PubMed ID: 30382824
[TBL] [Abstract][Full Text] [Related]
40. Efficacy and safety of anti-CD20 antibody rituximab for patients with refractory systemic lupus erythematosus.
Iwata S; Saito K; Hirata S; Ohkubo N; Nakayamada S; Nakano K; Hanami K; Kubo S; Miyagawa I; Yoshikawa M; Miyazaki Y; Yoshinari H; Tanaka Y
Lupus; 2018 Apr; 27(5):802-811. PubMed ID: 29308726
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
